{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:07:34Z","timestamp":1789106854780,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteosarcoma is the most prevalent primary malignant bone tumor in adolescents, featuring prominent intratumoral heterogeneity, early pulmonary metastasis and stagnant survival improvement for metastatic\/chemoresistant patients. Altered lipid metabolism represents as a core adaptive hallmark of malignancy, whereas the prognostic implication and molecular regulatory functions of lipid metabolism-related long non-coding RNAs (LMRLs) remain poorly elucidated in osteosarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Single-cell RNA-seq data from GSE152048 and bulk transcriptomic and clinical data from TARGET-OS were integrated. Lipid metabolic activity, malignant cell-state transitions, and intercellular communication were evaluated using AUCell, Monocle, and CellChat, respectively. Lipid metabolism-related genes were identified by integrating single-cell differential expression analysis with WGCNA. A prognostic lncRNA signature was constructed using Pearson correlation, Cox regression, and LASSO analyses. Immune infiltration, tumor mutational burden, immune checkpoint expression, and drug sensitivity were further assessed. scTenifoldKnk-based virtual knockout screening was performed to predict downstream target genes of ELFN1-AS1, followed by comprehensive\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      functional validation of the ELFN1-AS1\/LYPLA1 regulatory axis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Single-cell analysis revealed marked lipid-metabolic heterogeneity across osteosarcoma cell populations, with dynamic remodeling along malignant cell-state transitions and enhanced communication between high-lipid-metabolism osteosarcoma cells and stromal or vascular compartments. By integrating single-cell and bulk transcriptomic evidence, 22 lipid metabolism-related candidate genes were identified, from which a five-LMRL signature comprising AL133410.1, AL596247.1, ELFN1-AS1, IL10RB-DT, and NECTIN3-AS1 was developed. This signature effectively stratified patients into prognostically distinct risk groups and remained an independent predictor of overall survival. Exploratory computational analyses indicated risk subgroups exhibited divergent immune landscapes, mutational profiles and predicted drug responsiveness. Virtual knockout screening prioritized LYPLA1 as the key downstream effector of ELFN1-AS1. Among the signature lncRNAs, ELFN1-AS1 was prominently upregulated in osteosarcoma tissues and cells and was associated with poor prognosis. Mechanistically, ELFN1-AS1 drives osteosarcoma progression by triggering LYPLA1-dependent lipid accumulation-associated phenotype. Pharmacological blockade of\n                      <jats:italic>de-novo<\/jats:italic>\n                      lipogenesis using orlistat (selective FASN inhibitor) attenuated ELFN1-AS1-driven oncogenic phenotypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study establishes an LMRL-based for osteosarcoma prognostic stratification that reflects immune, genomic and therapeutic heterogeneity. Combining virtual knockout screening and experimental validation, we characterize the oncogenic ELFN1-AS1\/LYPLA1 regulatory cascade as a potential biomarker and therapeutic target for precision management of osteosarcoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1945005","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:30:52Z","timestamp":1789104652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative single-cell and bulk transcriptomics uncovers a lipid metabolism-related lncRNA signature alongside the ELFN1-AS1\/LYPLA1 axis driving osteosarcoma progression"],"prefix":"10.3389","volume":"17","author":[{"given":"Xianfu","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Qilu Hospital of Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyue","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.1743","article-title":"Osteosarcoma, chondrosarcoma, and chordoma","volume":"36","author":"Whelan","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2103423","article-title":"New horizons in the treatment of osteosarcoma","volume":"385","author":"Meltzer","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","article-title":"Advances on immunotherapy for osteosarcoma","volume":"23","author":"Yu","year":"2024","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3838","article-title":"Translational biology of osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12929-024-01049-y","article-title":"Osteosarcoma in a ceRNET perspective","volume":"31","author":"Mosca","year":"2024","journal-title":"J BioMed Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.16","article-title":"Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy","volume":"13","author":"Gianferante","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00388-4","article-title":"Tumour fatty acid metabolism in the context of therapy resistance and obesity","volume":"21","author":"Hoy","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7150\/thno.82920","article-title":"The role of lipid metabolic reprogramming in tumor microenvironment","volume":"13","author":"Yang","year":"2023","journal-title":"Theranostics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mco2.27","article-title":"Lipid metabolism in cancer progression and therapeutic strategies","volume":"2","author":"Fu","year":"2021","journal-title":"MedComm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.07.021","article-title":"Precise targeting of lipid metabolism in the era of immuno-oncology and the latest advances in nano-based drug delivery systems for cancer therapy","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2025.100660","article-title":"Lipid metabolic reprogramming and associated ferroptosis in osteosarcoma: from molecular mechanisms to potential targets","volume":"51","author":"Yin","year":"2025","journal-title":"J Bone Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/thno.41388","article-title":"Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2022.05.027","article-title":"Integrated lncRNA function upon genomic and epigenomic regulation","volume":"82","author":"Herman","year":"2022","journal-title":"Mol Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12964-024-01599-6","article-title":"Super enhancer lncRNAs: a novel hallmark in cancer","volume":"22","author":"Song","year":"2024","journal-title":"Cell Communication Signaling CCS"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-022-00566-8","article-title":"Long non-coding RNAs: definitions, functions, challenges and recommendations","volume":"24","author":"Mattick","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics - challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217297","article-title":"LncRNAs and the cancer epigenome: mechanisms and therapeutic potential","volume":"605","author":"Nadhan","year":"2024","journal-title":"Cancer Lett"},{"key":"B20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-022-00975-3","article-title":"Targeting non-coding RNAs to overcome cancer therapy resistance","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12967-025-07564-2","article-title":"Long non-coding RNAs in osteosarcoma: multifaceted regulators of Malignancy and therapeutic resistance","volume":"24","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109627","article-title":"Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma","volume":"121","author":"Wang","year":"2020","journal-title":"Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7150\/thno.99197","article-title":"Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism","volume":"14","author":"Zhao","year":"2024","journal-title":"Theranostics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-023-00803-9","article-title":"Advances in osteosarcoma","volume":"21","author":"Panez-Toro","year":"2023","journal-title":"Curr Osteoporosis Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188962","article-title":"Intratumoral lipid metabolic reprogramming as a pro-tumoral regulator in the tumor milieu","volume":"1878","author":"Wang","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201606","article-title":"Lipid metabolism and cancer","volume":"218","author":"Bian","year":"2021","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1042\/ebc20200032","article-title":"Non-coding RNA in cancer","volume":"65","author":"Yan","year":"2021","journal-title":"Essays Biochem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcancer.2020.12.012","article-title":"lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions","volume":"75","author":"McCabe","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2020.101055","article-title":"Lipids in the tumor microenvironment: from cancer progression to treatment","volume":"80","author":"Corn","year":"2020","journal-title":"Prog Lipid Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2021.04.013","article-title":"Lipid metabolism in cancer: new perspectives and emerging mechanisms","volume":"56","author":"Broadfield","year":"2021","journal-title":"Dev Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.09.023","article-title":"The role of lipids in cancer progression and metastasis","volume":"34","author":"Martin-Perez","year":"2022","journal-title":"Cell Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s43018-023-00702-z","article-title":"Lipids as mediators of cancer progression and metastasis","volume":"5","author":"Vogel","year":"2024","journal-title":"Nat Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1038\/s41467-023-41318-2","article-title":"Single-cell transcriptome analysis indicates fatty acid metabolism-mediated metastasis and immunosuppression in male breast cancer","volume":"14","author":"Sun","year":"2023","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk2756","article-title":"Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis","volume":"14","author":"Wang","year":"2022","journal-title":"Sci Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156464","article-title":"Brusatol inhibits Malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K\/AKT and MAPK pathways","volume":"139","author":"Yuan","year":"2025","journal-title":"Phytomedicine Int J Phytotherapy Phytopharmacology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1186\/s12967-025-07128-4","article-title":"Hispidulin suppresses osteosarcoma by directly targeting FABP4 to disrupt lipid metabolism and inhibit the PI3K\/AKT pathway","volume":"23","author":"Yuan","year":"2025","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.66181","article-title":"Close interactions between lncRNAs, lipid metabolism and ferroptosis in cancer","volume":"17","author":"Huang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215798","article-title":"LncRNAs in tumor metabolic reprogramming and immune microenvironment remodeling","volume":"543","author":"Yang","year":"2022","journal-title":"Cancer Lett"},{"key":"B40","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13045-021-01194-z","article-title":"A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.128412","article-title":"A novel lung cancer stem cell extracellular vesicles lncRNA ROLLCSC modulate non-stemness cancer cell plasticity through miR-5623-3p and miR-217-5p targeting lipid metabolism","volume":"256","author":"Zhang","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12920-023-01553-4","article-title":"Identification of two novel lipid metabolism-related long non-coding RNAs (SNHG17 and LINC00837) as potential signatures for osteosarcoma prognosis and precise treatment","volume":"16","author":"Tang","year":"2023","journal-title":"BMC Med Genomics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12885-024-11901-x","article-title":"LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism","volume":"24","author":"Cai","year":"2024","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844142","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","article-title":"Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response","volume":"14","author":"Fu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12943-025-02491-8","article-title":"Therapeutic targeting of cell death-immune crosstalk in cancer to rewire the tumor immune microenvironment","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-023-01843-3","article-title":"Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer","volume":"28","author":"Yao","year":"2023","journal-title":"Apoptosis Int J Programmed Cell Death"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1027449","article-title":"A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer","volume":"13","author":"Bai","year":"2022","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.143014","article-title":"Single-cell and bulk RNA-sequence identify an immune-derived lncRNA-mRNA signature for predicting clinical outcomes and immunotherapeutic response of prostate cancer","volume":"309","author":"Liu","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12967-025-06251-6","article-title":"A novel stemness-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity of clear cell renal cell carcinoma","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32231","article-title":"Identification of immune-related tumor antigens and immune subtypes in osteosarcoma","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00917-3","article-title":"A tumor microenvironment-based prognostic index for osteosarcoma","volume":"30","author":"Wu","year":"2023","journal-title":"J BioMed Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1424950","article-title":"Comprehensive investigation of tumor immune microenvironment and prognostic biomarkers in osteosarcoma through integrated bulk and single-cell transcriptomic analysis","volume":"15","author":"Shi","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1945005\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:30:54Z","timestamp":1789104654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1945005\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2026.1945005"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1945005","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1945005"}}